LBP as a biomarker in oral and maxillofacial tumors
View/ Open
File version
Accepted Manuscript (AM)
Author(s)
Qiao, Bin
Chen, Zhuo
Huang, Junwen
Lam, Alfred King-Yin
Mei, Zi
Li, Yang
Qiao, Jie
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
Oral and Maxillofacial tumors (OMTs), such as oral squamous cell carcinoma (SCC), pleomorphic adenoma and ameloblastoma, are common head and neck tumors. Lipopolysaccharide binding protein (LBP) is a type I acute reactive protein, which participates in body inflammatory response modulation through lipopolysaccharide (LPS)-induced signaling pathway by targeting macrophages (expressing cluster of differentiation 204 (CD204). Although it is well established that LBP is associated with the development of multiple types of cancer, little is known about the role of LBP in OMTs. This study aims to explore the expression of LBP in ...
View more >Oral and Maxillofacial tumors (OMTs), such as oral squamous cell carcinoma (SCC), pleomorphic adenoma and ameloblastoma, are common head and neck tumors. Lipopolysaccharide binding protein (LBP) is a type I acute reactive protein, which participates in body inflammatory response modulation through lipopolysaccharide (LPS)-induced signaling pathway by targeting macrophages (expressing cluster of differentiation 204 (CD204). Although it is well established that LBP is associated with the development of multiple types of cancer, little is known about the role of LBP in OMTs. This study aims to explore the expression of LBP in OMTs. Here immunohistochemical (IHC) double-staining of LBP and CD204 and enzyme-linked immunosorbent assay (ELISA) were conducted to explore the LBP expression in OMTs. The findings demonstrated that the LBP expression in OMTs was significantly elevated (P<0.001). In addition, the LBP expression was associated with the clinical stage (P<0.001), T-classification (P<0.001) and lymph node metastasis (P<0.001, except ELISA) but independent of histological grade of SCC, gender and age in patients with SCC. The optional cutoff of the LBP serum level is 0.721μg/ml. To conclude, LBP contributes to the development of OMTs and could be a biomarker in the screening and predicting metastasis in patients with OMTs.
View less >
View more >Oral and Maxillofacial tumors (OMTs), such as oral squamous cell carcinoma (SCC), pleomorphic adenoma and ameloblastoma, are common head and neck tumors. Lipopolysaccharide binding protein (LBP) is a type I acute reactive protein, which participates in body inflammatory response modulation through lipopolysaccharide (LPS)-induced signaling pathway by targeting macrophages (expressing cluster of differentiation 204 (CD204). Although it is well established that LBP is associated with the development of multiple types of cancer, little is known about the role of LBP in OMTs. This study aims to explore the expression of LBP in OMTs. Here immunohistochemical (IHC) double-staining of LBP and CD204 and enzyme-linked immunosorbent assay (ELISA) were conducted to explore the LBP expression in OMTs. The findings demonstrated that the LBP expression in OMTs was significantly elevated (P<0.001). In addition, the LBP expression was associated with the clinical stage (P<0.001), T-classification (P<0.001) and lymph node metastasis (P<0.001, except ELISA) but independent of histological grade of SCC, gender and age in patients with SCC. The optional cutoff of the LBP serum level is 0.721μg/ml. To conclude, LBP contributes to the development of OMTs and could be a biomarker in the screening and predicting metastasis in patients with OMTs.
View less >
Journal Title
Oral DisOral Diseases
Copyright Statement
© 2021 John Wiley & Sons A/S. This is the peer reviewed version of the following article: LBP as a biomarker in oral and maxillofacial tumors, Oral Diseases, 2021, which has been published in final form at https://doi.org/10.1111/odi.14042. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
Subject
Dentistry
CD204
LBP
SCC
ameloblastoma
biomarker